Information may be obtained or stored in your browser by cookies when you access the Website. This information is related to the user, the user settings or device. It is primarily used to ensure the site functions as expected by the user. We respect your right to privacy. Therefore, you can select to not allow some types of cookie. Please click on the different category headings to check the details and then change our default settings.
Strictly Necessary Cookies are cookies that are essential for this site to function properly. Strictly Necessary Cookies do not store information that can identify individuals. Strictly Necessary Cookies are used to view this site. Therefore, you cannot refuse the use of Strictly Necessary Cookies from these cookie settings. However, you can refuse the use of Strictly Necessary Cookies from the settings of your browser at any time. Please note that parts of the site may not function if you refuse the use of Strictly Necessary Cookies.
This site uses the following Strictly Necessary Cookies.
Cookie name: gdprCookieEn
Cookie name: optGA
Cookie name: optPardot
Nippon Kayaku's history of anti-cancer drugs began with the launch of BREO® in 1969, and has various product lineup of many anti-cancer drugs. On the basis of Nippon Kayaku's network of cancer-specialist medical representatives, highly reliable information can be rapidly provided to physicians, pharmacists and nurses at clinical institutions. In recent years, we have been furthering our efforts into the areas of biosimilar products, generic anti-cancer drugs, as well as medical device so that we can continue to provide highly necessary pharmaceuticals and medical device for patients along with exceptionally reliable information to the medical institutions.
We will continue to develop outstanding pharmaceuticals and medical devices, provide new diagnostic and therapeutic opportunities, and have a stable supply of biosimilars and generics, thereby contributing to the realization of sustainable society and people's health.